- Switching to Tremfya at week 28 after inadequate response to Humira, led to a sustained improvement
- Tremfya is a human monoclonal antibody
The Janssen Pharmaceutical... read more
The Janssen Pharmaceutical... read more
OncoResponse announced on 9/11/18 the completion of a... read more
OPKO Health, Inc. (NASDAQ:OPK) has had trading in its common stock halted by The Nasdaq Stock Market, and the exchange has advised OPKO that the halt will continue until the company responds (to... read more
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) announced on 9/10/18 publication of additional data from a Phase 2 single center, double-blind, placebo-controlled study to examine the safety and... read more
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,